Please login to the form below

Not currently logged in
Email:
Password:

Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

He takes up a seat on the company's board of directors

Amylyx Dr Walter GilbertThe founder and former chief executive officer of Biogen Dr Walter Gilbert has been elected to Amylyx Pharmaceuticals' board of directors.

The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

Justin Klee, co-founder and president of Amylyx, said: “Dr Gilbert brings an enormous breadth of experience as a scientist, biotech founder and executive.

“We are honoured that he will join our efforts to advance AMX0035 for the treatment of ALS, which will be tested in an initial clinical trial in patients later this year.”

Over his 40-year career in industry and academia, Dr Gilbert founded several life sciences companies, including Biogen where he was chief executive officer and chairman of the board between 1981 and 1985, and Myriad Genetics where he continues to serve as vice chairman of its board of directors.

Dr Gilbert received the Nobel Prize in Chemistry in 1980 for the development of a rapid method of DNA sequencing, and is currently the Carl M. Loeb University Professor Emeritus at Harvard University.

He said: “Amylyx has assembled an outstanding team that is advancing an innovative approach to ALS and other neurodegenerative diseases.

“I am excited to help bring this promising therapeutic to patients.”

26th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics